<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676793</url>
  </required_header>
  <id_info>
    <org_study_id>H04-179</org_study_id>
    <nct_id>NCT00676793</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression</brief_title>
  <official_title>Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-Met Signaling and Activation of Pathways Contributing to Breast Cancer Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisiana State University Health Sciences Center Shreveport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Louisiana State University Health Sciences Center Shreveport</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see if an extract of green tea can affect certain markers of breast cancer and breast
      cancer progression in women with a recent biopsy positive for cancer and who are scheduled
      for surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the short-term effects of a daily dose of Polyphenon E administered during the
      interval between breast biopsy and surgery in women with recently diagnosed breast cancer.
      Endpoints will be changes in serum and tissue biomarkers related to progression of cancer.

      The effect of Polyphenon E on tumor cell c-Met expression and phosphorylation is the primary
      objective. Secondary objectives include the effects on the other tissue and serum biomarkers.
      Evaluation of the safety and tolerability of Polyphenon E in this subject population is
      another objective.

      1.1 Determine the effects of Polyphenon E on tumor cell c-Met expression and phosphorylation
      levels in patients with breast cancer

      1.2 Determine the effects of Polyphenon E on PI-3K activation in patients with breast cancer

      1.3 Determine the effects of Polyphenon E on MAPK activation in patients with breast cancer

      1.4 Determine the effects of Polyphenon E on expression levels of other proteins involved in
      motility and invasion such as Rho GTPases and extracellular proteinases in patients with
      breast cancer

      1.5 Determine the effects of Polyphenon E on markers of angiogenesis in patients with breast
      cancer

      1.6 Determine the effects of Polyphenon E on other serum markers: C-reactive protein (CRP),
      Insulin-Like Growth factor I (IGF-I), Insulin-like Growth Factor Binding Protein 3 (IGFBP-3)
      and Hepatocyte Growth Factor HGF

      1.7 Evaluate the safety and tolerability of Polyphenon E in this subject population
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum VEGF in Breast Cancer</measure>
    <time_frame>Baseline and 4 to 6 weeks</time_frame>
    <description>Change in serum VEGF from baseline to post treatment with polyphenon E.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum HGF and Breast Cancer</measure>
    <time_frame>Baseline and 4 to 6 weeks</time_frame>
    <description>Change in serum HGF from baseline to post Polyphenol E treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Polyphenon E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm study comparing changes within patients before and after receiving the experimental drug Polyphenon E for the duration of the study, between recruitment and surgery for breast cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyphenon E</intervention_name>
    <description>Four 200mg capsules daily taken with a meal, for the duration of the study.</description>
    <arm_group_label>Polyphenon E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definitive biopsy demonstrating primary breast cancer

          -  Residual breast cancer requiring additional surgical resection

          -  Stage I, II or III disease

          -  Patient has ability to give signed informed consent

          -  Normal hepatic and renal function (creatinine&lt;1.5, transaminases &lt;1.5 times upper
             limit of normal).

          -  ECOG Performance status of 0 or 1.

          -  Age â‰¥ 21 years and less than 75

        Exclusion Criteria:

          -  Prior hormonal or surgical therapy for breast cancer

          -  Abnormal liver function test

          -  Liver or kidney problems that would interfere with metabolism of study drug

          -  Any condition that would hamper informed consent or ability to comply with study
             protocol

          -  Participation in another research study in the last three months

          -  Known malignancy at any site other than breast

          -  Recent consumption of green tea (5 or more cups per day, within one week prior to
             biopsy)

          -  Allergy or intolerance to any component of green tea

          -  Inability or refusal to comply with definitive surgical therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Burton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSU Health Sciences Center Shreveport</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LSU Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Proffered Oral Presentations - Intervention Studies Abstract PR-05: Effects of presurgical administration of tea polyphenols in women with operable breast cancer Julie L. Campbell1, James Cardelli2, Jerry McLarty2, Dawn Hershman1, Bret Taback1, Susan Refice1, Stephanie Wang2, Rebecca Bigelow2 and Katherine Crew1 1Columbia University Medical Center, New York, NY 2Louisiana State University Health Sciences Center, Shreveport, LA Cancer Prevention Research: December 2010; Volume 3, Issue 12, Supplement 2. doi: 10.1158/1940-6207.PREV-10-PR-05</citation>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <results_first_submitted>September 2, 2011</results_first_submitted>
  <results_first_submitted_qc>September 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2012</results_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center Shreveport</investigator_affiliation>
    <investigator_full_name>Jerry McLarty</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>EGCG</keyword>
  <keyword>Polyphenon E</keyword>
  <keyword>c-Met</keyword>
  <keyword>VEGF</keyword>
  <keyword>HGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ECGC and Breast Cancer</title>
          <description>Single arm for a phase II study of EGCG extract and breast cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ECGC and Breast Cancer</title>
          <description>Single arm for a phase II study of EGCG extract and breast cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum VEGF in Breast Cancer</title>
        <description>Change in serum VEGF from baseline to post treatment with polyphenon E.</description>
        <time_frame>Baseline and 4 to 6 weeks</time_frame>
        <population>Number of participants for analysis was determined per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>ECGC and Breast Cancer</title>
            <description>Single arm for a phase II study of EGCG extract and breast cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum VEGF in Breast Cancer</title>
          <description>Change in serum VEGF from baseline to post treatment with polyphenon E.</description>
          <population>Number of participants for analysis was determined per protocol.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="-142.5" upper_limit="581.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no change, i.e. median change=0.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.078</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum HGF and Breast Cancer</title>
        <description>Change in serum HGF from baseline to post Polyphenol E treatment.</description>
        <time_frame>Baseline and 4 to 6 weeks</time_frame>
        <population>Number of participants for analysis was determined per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>ECGC and Breast Cancer</title>
            <description>The effect of ECGC extract on biomarkers in breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum HGF and Breast Cancer</title>
          <description>Change in serum HGF from baseline to post Polyphenol E treatment.</description>
          <population>Number of participants for analysis was determined per protocol.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.0" lower_limit="-143.75" upper_limit="700.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no change, i.e. median change=0.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.094</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ECGC and Breast Cancer</title>
          <description>Single arm for a phase II study of EGCG extract and breast cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and then again at presurgery, the end point for the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in amylase and lypase</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jerry w. McLarty, Ph.D.</name_or_title>
      <organization>LSU Health, Shreveport</organization>
      <phone>(318)813-1446</phone>
      <email>jmclar@lsuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

